TMO EPM / Hemato H9J
TMO EPM / Hemato H9J
Podcast de discussão de assuntos em Hematologia do Transplante de Medula Óssea da Escola Paulista de Medicina (UNIFESP) e da Hematologia do Hospital 9 de Julho - DASA
Autor
TMO EPM / Hemato H9J
Kategorie
Podcast-Website
Neueste Folge
6. Jul 2026
Wo hören?
Podcasts in der App Replaio Radio Bald verfügbarPodcasts kommen bald in die App. Installiere sie jetzt und erlebe als Erster einen ganz neuen Blick auf Podcasts
Kostenlos installieren
Android fast 10 Mio. Downloads · Bewertung 4,8
iOS bald
Folgen
52 - Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia 29.04.2025 40:35
Discussão do artigo: "Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia" de Chalandon Y Blood 2024 Apresentado por: Dr. Matheus Maia Discussão por: Dra. Gabriele Ritter, Dr. Rafael Faust, Dra. Amanda Chucre, Dr. Pedro Moraes e Dr. Vinícius Molla
51 - Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia 13.04.2025 35:13
Discussão do artigo: "Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia" de Brown J NEJM 2025 Apresentado por: Dra. Camila Frade Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr. Rafael Faust, Dra. Camila Ferreira e Dr. Vinícius Molla
50 - Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia 07.04.2025 26:45
Discussão do artigo: "Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia" de Roddie C NEJM 2024 Apresentado por: Dr. Gabriel Coquito Discussão por: Dr. Rafael Faust, Dra. Camila Ferreira e Dr. Pedro Moraes
49 - Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation 18.03.2025 35:00
Discussão do artigo: "Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation" de Kumar A Blood 2025 Apresentado por: Dr. Lucas Salviano Discussão por: Dr. Rafael Faust, Dra. Camila Ferreira e Dr. Vinicius Molla
48 - Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma 16.03.2025 26:35
Discussão do artigo: "Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma" de Cohen Y NEJM 2025 Apresentado por: Dr. Matheus Puls Discussão por: Dr. Breno Aires, Dra. Camila Ferreira, Dr. Rafael Faust, Dr. Pedro Arruda e Dr. Vinicius Molla
47 - Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma 11.03.2025 32:29
Discussão do artigo: "Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma" de Dimopoulos M NEJM 2024 Apresentado por: Dra. Thais Araujo Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr. Pedro Arruda e Dr. Vinicius Molla
46 - Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study 29.12.2024 35:25
Discussão do artigo: "Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study" de Badros A Blood 2024 Apresentado por: Dr. Matheus Puls Discussão por: Dr. Rafael Faust, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla
45 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma 26.12.2024 30:37
Discussão do artigo: "Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma" de Facon T NEJM 2024 Apresentado por: Dra. Marcella Markman Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr. Matheus Puls, Dr. Pedro Arruda e Dr. Vinicius Molla
44 - Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML 23.12.2024 34:09
Discussão do artigo: "Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML" de Rollig C JCO 2024 Apresentado por: Dra. Luana Pompeu Discussão por: Dr. Rafael Faust, Dr. Breno Aires, Dr. Eurides Rosa, Dr. Pedro Arruda e Dr. Vinicius Molla
43 - Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma 27.11.2024 29:15
Discussão do artigo: "Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma" de Herrera AF NEJM 2024 Apresentado por: Dra. Aline Guerra Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr. Pedro Arruda e Dr. Vinicius Molla
42 - Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21) 23.11.2024 36:44
Discussão do artigo: "Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21)" de Borchmann P Lancet 2024 Apresentado por: Dr. Gabriel Coquito Discussão por: Dr. Rafael Faust, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla
41 - An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease 01.11.2024 27:50
Discussão do artigo: "An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease" de Kassim A BLOOD 2024 Apresentado por: Dra. Aline Guerra Discussão por: Dr. Rafael Faust, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla
40 - Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission 27.09.2024 20:09
Discussão do artigo: "Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission" de Shadman M Blood cancer journal 2024 Apresentado por: Dra. Camila Frade Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr. Pedro Arruda e Dr. Vinicius Molla
39 - Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors 25.09.2024 30:59
Discussão do artigo: "Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors" de Shaffer B JCO 2024 Apresentado por: Dra. Marcela Markmann Discussão por: Dr. Rafael Faust, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla
38 - Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma 19.09.2024 40:39
Discussão do artigo: "Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma" de Hungria V NEJM 2024 Apresentado por: Dr. Matheus Puls Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dra. Aline Guerra, Dr. Pedro Arruda e Dr. Vinicius Molla
37 - Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults 24.08.2024 34:44
Discussão do artigo: "Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults" de Litzow MR NEJM 2024 Apresentado por: Dr. Gabriel Coquito Discussão por: Dr. Lucas Salviano, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla
36 - Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma 16.08.2024 24:48
Discussão do artigo: "Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma" de Melani C NEJM 2024 Apresentado por: Dra. Aline Guerra Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr. Pedro Arruda e Dr. Vinicius Molla
35 - A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia 05.08.2024 24:43
Discussão do artigo: "A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia" de Metheny L Blood Adv. 2024 Mar 26;8(6):1384-1391 Apresentado por: Dra. Thais Araujo Discussão por: Dr. Rafael Faust, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla
34 - Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission 27.07.2024 28:40
Discussão do artigo: "Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission " de Othman J Blood 2024 Apresentado por: Dra. Luana Pompeu Discussão por: Dr. Rafael Faust, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla
33 - Asciminib in Newly Diagnosed Chronic Myeloid Leukemia 14.07.2024 31:35
Discussão do artigo: "Asciminib in Newly Diagnosed Chronic Myeloid Leukemia" de Hochhaus A NEJM 2024 Apresentado por: Dra. Camila Frade Discussão por: Dr. Lucas Salviano, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla.
32 - The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial 12.07.2024 33:43
Discussão do artigo: "Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma" de Koji Kato Bone Marrow Transplantation 2024 Apresentado por: Dra Marcella Markman Discussão por: Dr. Rafael Faust, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla
31 - Remission induction vs immediate allogeneic HSCT for patients with relapsed or poor responsive AML (ASAP): a randomised, open-label, phase 3, non-inferiority trial 05.07.2024 20:18
Discussão do artigo: "Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial" de Stelljes M Lancet Haematol 2024. Apresentado por: Dr Gabriel Coquito
30 - Ibrutinib combined with immunochemotherapy with or without ASCT vs immunochemotherapy and ASCT in previously untreated patients with mantle cell lymphoma (TRIANGLE) 03.07.2024 33:50
Discussão do artigo: "Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE)" de Dreyling M Lancet 2024; 403: 2293–306 Apresentado por: Dra Thais Araujo Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr....
29 - Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT 27.05.2024 22:21
Discussão do artigo: "Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT" de Sanz J Blood 2024 Apresentado por: Dra Luana Pompeu Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr. Gabriel Coquito, Dr. Pedro Arruda e Dr. Vinicius Molla.
28 - Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial 24.04.2024 23:09
Discussão do artigo: "Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial" de Stella F Blood Advances 2023 Apresentado por: Dra Camila Frade Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr. Matheus Puls, Dr. Pedro Arruda e Dr. Vinicius Molla.
Ähnliche Podcasts
Höre den Podcast TMO EPM / Hemato H9J in Replaio
Radio und Podcasts in einer App - kostenlos und ohne Anmeldung. Installiere sie noch heute und verpasse den Start nicht
Replaio ist kein Herausgeber von Podcasts; die Namen der Sendungen, Cover und Audioinhalte gehören ihren Autoren und werden über öffentliche RSS-Feeds verbreitet
